CI&T (CINT) Q2 2026 Earnings Call Transcript

CI&T (CINT) reported Q2 2026 revenue of $142.8M, up 21.9% YoY, exceeding guidance. Full-year revenue guidance raised to $566M-$578M. Adjusted EBITDA was $19M with a 13.3% margin. Sales pipeline expanded 40% YoY, driven by AI demand. Financial services and tech/telecom verticals grew 36% and 68% YoY, respectively. Consumer goods revenue declined 9% YoY. Management highlighted investments in AI and value-based pricing models.

Original reporting
Published Aug 19, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CI&T (CINT) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CINTBullishMed
01

Why it matters

The earnings beat and raised guidance signal stronger-than-expected demand for AI‑enabled services, potentially prompting re‑rating by analysts.

02

Market read

First‑time earnings disclosure with upgraded guidance offers a fresh catalyst for traders; AI‑centric growth aligns with sector momentum.

03

What to watch

Currency appreciation risk and the modest consumer‑goods contraction may limit near‑term profitability.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

CI&T is a Brazil‑based digital transformation firm listed on NASDAQ under CINT, reporting its Q2 2026 results.

Company-level read

Ticker impact

$CINTBullishHigh confidence
Context

Q2 2026 earnings disclosed net revenue of $142.8M, raised full-year revenue guidance to $566‑$578M and provided updated margin outlook.

Expected impact

Potential price appreciation on earnings beat and upgraded guidance, especially if market pricing was below expectations.

Evidence & confidence

First‑time disclosure of earnings and guidance for the quarter, with material beat and forward‑looking growth metrics, provides a clear actionable catalyst.

Market effects

Highlights accelerating AI services demand in technology and financial services sectors.

Strong growth in Latin America and North America may boost regional tech exposure.

AI‑driven revenue growth resonates with broader market themes on automation and digital transformation.

Counterpoint

Margin headwinds from foreign‑exchange and slower consumer‑goods demand could temper upside.

Key entities

  • CI&T Inc.

    Digital transformation and AI services provider.

  • Eduardo Galvao

    Director of Investor Relations, presented earnings.

Related articles

$CINTMed

CI&T Inc (CINT) (Q3 2026) Earnings Call Highlights: Record Revenue and AI-Driven

CI&T Inc (CINT) reported Q3 2026 revenue growth of 14.9% YoY, but adjusted EBITDA declined 3.9% due to FX and payroll tax headwinds. Q4 guidance is $142.3M-$152.0M, with deceleration due to macro uncertainty. Gross margin expanded sequentially due to AI-driven productivity and value-based models, but organic growth slowed. The pipeline is up 50% YoY, with 70% from existing clients. AI partnerships and value-based models are expected to drive 2027 growth.

$CINTLow

What CI&T (CINT) Said on Its Q3 Earnings Call

CI&T (CINT) reported Q3 adjusted EBITDA fell 3.9% YoY due to currency effects, but rose 3.4% on a currency-neutral basis to $24.3M. Revenue from non-top-10 clients grew 17.1% YoY, outpacing top clients' 12.2% growth. Adjusted profit increased 2% to $11.5M. The company forecasted Q4 revenue of $142.3M-$152.0M and raised its 2026 revenue outlook to $568M-$578M.

MedAI 8/10

CI&T Inc Q2 2026 Earnings Call Summary

CI&T Inc reported Q2 2026 results and said record revenue growth reflects a shift to AI deployments and value-based pricing. Adjusted gross margin rose to 32.4%. Full-year revenue guidance was raised to $566 million to $578 million, with adjusted EBITDA margin at 15% to 17% amid FX headwinds and planned AI investments.

$SGPMedAI 8/10

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates • Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatopro

$ONDSHighAI 8/10

Ondas Posts Record Q3 2026 Revenue of $167.5 Million on Strong Bookings and Backlog Growth; Raises Full-Year Outlook

Ondas Inc. (ONDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ondas Posts Record Q3 2026 Revenue of $167.5 Million on Strong Bookings and Backlog Growth; Raises Full-Year Outlook Record Q3 revenue of $167.5 million, up 100% sequentially and more than 16-fold year over year; pro forma organic revenue grew 64% year-over-year Capt